Insmed (INSM) Q2 2026 earnings review
A Historic Launch Subsidizes Pipeline Expansion, But Mind the Accounting
Insmed is executing what could be one of the most successful commercial launches in biopharma history. BRINSUPRI generated $309.2 million in its third full quarter, driving total company revenue up 296% YoY to $425.5 million. This massive top-line acceleration led management to hike full-year BRINSUPRI guidance to $1.25-$1.40 billion and drastically raise peak sales estimates for its top three assets to over $14 billion. The headline Net Loss reversed sharply to just $13.2 million from a $321.7 million loss a year ago. However, the optics of this near-breakeven quarter are heavily skewed by a one-time $99.8 million non-cash accounting benefit. Stripping that out, underlying operating burn remains substantial as the company aggressively funds its sales force and multiple Phase 3 trials.
🐂 Bull Case
BRINSUPRI's launch continues to break records, growing 49% sequentially and tracking toward blockbuster status in its first full year. The drug has completely transformed Insmed's P&L.
Confidence is soaring: peak revenue estimates for BRINSUPRI were bumped from $5B+ to $7B+, and TPIP's target tripled from $2B+ to $6B+, reflecting expanding TAMs and positive clinical readouts.
🐻 Bear Case
Excluding the $99.8M contingent consideration benefit, operating expenses were $526.8M. With $425.5M in revenue, the actual cash-burning operational gap is over $100M per quarter.
The threat of U.S. MFN (Most Favored Nation) pricing policies continues to effectively paralyze BRINSUPRI's international commercial rollout, capping the near-term global TAM.
⚖️ Verdict: 🟢
Bullish. While the headline profitability is an accounting mirage, the underlying fundamentals are spectacular. BRINSUPRI's 49% QoQ growth provides more than enough gross profit to aggressively fund a late-stage pipeline that was just re-rated to a $14 billion peak value.
Key Themes
BRINSUPRI Organic Demand is Accelerating
With the initial 'bolus' of waiting patients cleared in Q1, Q2 served as the first pure test of organic demand. The result was a staggering 49% sequential growth to $309.2 million. The rapid uptake drove an upward revision of FY26 guidance by roughly $250M at the midpoint. This confirms management's prior claims of high continuation rates and deep prescriber penetration.
TPIP Emerges as a $6 Billion Franchise
Management significantly de-risked TPIP, releasing positive 12-month OLE data in PAH showing ~60% reduction in NT-proBNP and ~80% of patients achieving WHO FC I or II status. Because the formulation allows safe titration to massive doses (up to 1,280 µg), the company tripled its peak revenue estimate for the asset to over $6 billion across four targeted indications (PAH, PH-ILD, PPF, IPF).
Profitability Narrative Contradicted by Accounting Adjustments
The reported GAAP operating loss of just $1.5 million is misleading. Operating expenses included a $99.8 million non-cash benefit from the 'Change in fair value of contingent consideration liabilities'. Without this accounting adjustment, total operating expenses would be $526.8 million against $425.5 million in revenue, yielding an underlying operating loss closer to $101 million. While improving, the company is burning cash faster than the headline net loss suggests.
Macro Risk: Ex-US Launch Frozen by US Policy
Management explicitly stated they continue to evaluate 'evolving U.S. policies' affecting international timing. This references the previously cited MFN (Most Favored Nation) pricing risk. Insmed refuses to launch BRINSUPRI in Europe or the UK out of fear that lower foreign prices could be imported into the US market via legislation. This effectively caps BRINSUPRI as a US-only asset in the near term.
ARIKAYCE Label Expansion Submitted
Insmed submitted an sNDA to the FDA in July 2026 for ARIKAYCE in newly diagnosed MAC lung disease. An expanded label would transition the drug from a salvage therapy (~30,000 patients) to a frontline option (>200,000 patients). Management reiterated a peak revenue target of >$1 billion, which depends entirely on this regulatory execution.
US ARIKAYCE Growth is Decelerating
While total ARIKAYCE revenue grew 8% YoY, underlying US growth is decelerating and nearly flat at 2% YoY ($70.2M vs $68.7M). The segment's growth was entirely propped up by International sales, which grew 19% YoY. Until the label expansion is approved, US ARIKAYCE is a stable but stagnant legacy asset.
Other KPIs
Cost of product revenues (excluding amortization) was $67.2M, yielding an 84.2% gross margin. This is a dramatic acceleration in profitability profile compared to Q2 2025 (73.9% gross margin). Because BRINSUPRI (a small molecule pill) is significantly cheaper to manufacture than ARIKAYCE (a liposomal suspension), the revenue mix shift is generating massive gross profit leverage.
Combined R&D ($210.0M) and SG&A ($247.5M) spending surged 38% YoY from $332M in 25Q2. The SG&A explosion is directly tied to the commercial build-out for BRINSUPRI, while R&D reflects the aggressively expanding TPIP Phase 3 program. The company has the revenue to support this, but overhead is far from stable.
Guidance
Accelerating. Raised significantly from previous guidance of 'at least $1 billion'. Achieving the midpoint ($1.325B) implies the back half of the year must average roughly $404 million per quarter, necessitating continued robust quarter-over-quarter expansion.
Stable. Reiterated. The midpoint ($460M) implies roughly 6% YoY growth from FY25 ($433.8M). Given H1 2026 revenue is $214.4M, the company must generate ~$245.6M in H2, relying heavily on continued international outperformance.
Key Questions
True Operational Cash Burn
Excluding the $99.8M fair value adjustment on contingent consideration, operating losses were still over $100M this quarter. Can you detail the anticipated trajectory of cash SG&A and R&D spend for the second half of the year?
International BRINSUPRI Strategy
You noted evaluating 'evolving U.S. policies' regarding international launches. What specific policy clarity or legislative outcome do you need to see before feeling comfortable launching BRINSUPRI in Europe or Japan?
US ARIKAYCE Stagnation
US ARIKAYCE revenue grew just 2% YoY this quarter. Has the US refractory market reached full saturation, and should we expect flat-to-negative US revenue until the sNDA for newly diagnosed patients is potentially approved?
TPIP Trial Enrollment Pace
With the massive upgrade to TPIP's peak sales estimates, how is the enrollment velocity trending in the PALM-ILD and PALM-PAH trials, particularly given the competitive prostanoid landscape?